These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 12833009)

  • 21. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
    Shephard SE; Panizzon RG
    Dermatology; 1999; 199(2):106-12. PubMed ID: 10559574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phototesting in bath-PUVA: marked reduction of 8-methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath.
    Schempp CM; Schöpf E; Simon JC
    Photodermatol Photoimmunol Photomed; 1996 Jun; 12(3):100-2. PubMed ID: 8956358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of UV-B erythema of psoralen, trimethylpsoralen, and 8 methoxypsoralen.
    Coupez L; Agache PG; Petigny M
    Acta Derm Venereol; 1980; 60(5):456-9. PubMed ID: 6162327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of PUVA on langerhans cells in rat oral epithelium photosensitized with systemic methoxsalen or topical trioxsalen.
    Kuusilehto A; Happonen RP; Peltola J; Lehtinen R; Jansén CT
    Photodermatol Photoimmunol Photomed; 2000 Jun; 16(3):129-33. PubMed ID: 10885443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema.
    De Rie MA; Van Eendenburg JP; Versnick AC; Stolk LM; Bos JD; Westerhof W
    Br J Dermatol; 1995 Jun; 132(6):964-9. PubMed ID: 7662576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PUVA therapy for photosensitive psoriasis.
    Ros AM; Wennersten G
    Acta Derm Venereol; 1987; 67(6):501-5. PubMed ID: 2451375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time course of 8-methoxypsoralen-induced skin photosensitization in PUVA-bath photochemotherapy.
    Reuther T; Gruss C; Behrens S; von Kobyletzki G; Neumann N; Lehmann P; Altmeyer P; Kerscher M
    Photodermatol Photoimmunol Photomed; 1997; 13(5-6):193-6. PubMed ID: 9542757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of treatment frequency and UVA dose does not substantially compromise the antipsoriatic effect of oral psoralen-UVA.
    Legat FJ; Hofer A; Quehenberger F; Kahofer P; Kerl H; Wolf P
    J Am Acad Dermatol; 2004 Nov; 51(5):746-54. PubMed ID: 15523353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen.
    Tegeder I; Bräutigam L; Podda M; Meier S; Kaufmann R; Geisslinger G; Grundmann-Kollmann M
    Clin Pharmacol Ther; 2002 Mar; 71(3):153-61. PubMed ID: 11907489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of photosensitivity in bath-PUVA photochemotherapy.
    Gruss C; Behrens S; Reuther T; Husebo L; Neumann N; Altmeyer P; Lehmann P; Kerscher M
    J Am Acad Dermatol; 1998 Sep; 39(3):443-6. PubMed ID: 9738780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction in 8-methoxypsoralen immersion time alters the erythemal response to bath PUVA.
    Azurdia RM; Dean MP; Rhodes LE
    Photodermatol Photoimmunol Photomed; 2000 Aug; 16(4):186-8. PubMed ID: 11019945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the skin concentrations after administration of the various phototoxic drugs.
    Park YK; Hann SK; Cho MY; Kim HJ; Shim SC; Choi SJ; Yun MH
    Yonsei Med J; 1991 Sep; 32(3):231-6. PubMed ID: 1781182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5',8-trimethylpsoralen, and psoralen in vitiligo.
    Pathak MA; Mosher DB; Fitzpatrick TB
    Natl Cancer Inst Monogr; 1984 Dec; 66():165-73. PubMed ID: 6531024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bath PUVA and psoriasis: is a milder treatment a worse treatment?
    Delrosso G; Bornacina C; Farinelli P; Bellinzona F; Leigheb G; Colombo E
    Dermatology; 2008; 216(3):191-3. PubMed ID: 18182808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of PUVA bath phototoxicity.
    Neumann NJ; Kerscher M; Ruzicka T; Lehmann P
    Acta Derm Venereol; 1997 Sep; 77(5):385-7. PubMed ID: 9298134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between plasma psoralen concentration and psoralen-UVA erythema.
    Mclelland J; Fisher C; Farr PM; Diffey BL; Cox NH
    Br J Dermatol; 1991 Jun; 124(6):585-90. PubMed ID: 2064944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The time course of topical PUVA erythema following 15- and 5-minute methoxsalen immersion.
    Man I; Kwok YK; Dawe RS; Ferguson J; Ibbotson SH
    Arch Dermatol; 2003 Mar; 139(3):331-4. PubMed ID: 12622625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psoralen cream plus ultraviolet A photochemotherapy (PUVA cream): our experience.
    Pozo-Román T; González-López A; Velasco-Vaquero ME; Núñez-Cabezón M
    J Eur Acad Dermatol Venereol; 2006 Feb; 20(2):136-42. PubMed ID: 16441619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris. Evidence that epidermal immunocytes are direct therapeutic targets.
    Coven TR; Murphy FP; Gilleaudeau P; Cardinale I; Krueger JG
    Arch Dermatol; 1998 Oct; 134(10):1263-8. PubMed ID: 9801682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of methoxsalen dose on ultraviolet-A-induced erythema.
    Ibbotson SH; Dawe RS; Farr PM
    J Invest Dermatol; 2001 May; 116(5):813-5. PubMed ID: 11348476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.